[CAS NO. 1799706-65-2] MMAFsodium
PRODUCTS SPECIFICATIONS [1799706-65-2]
DESCRIPTION [1799706-65-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 753.94 |
| Molecular Formula | C39H64N5NaO8 |
| SMILES | CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C(O[Na])=O)CC2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O)C |
7 Publications Citing Use of MCE
Summary
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates ( ADC s) such as Vorsetuzumab mafodotin and SGN-CD19A [1] [2] [3] .
IC50 & Target
|
Auristatin |
In Vitro
MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC 50 s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : ≥ 200 mg/mL ( 265.27 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.3264 mL | 6.6318 mL | 13.2637 mL |
| 5 mM | 0.2653 mL | 1.3264 mL | 2.6527 mL |
| 10 mM | 0.1326 mL | 0.6632 mL | 1.3264 mL |
References
- [1] Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
- [2] Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
- [3] Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
- [4] Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
